公开(公告)号：US11292788B2

公开(公告)日：2022-04-05

申请号：US16644581

申请日：2018-09-06

申请人： Immunic AG

发明人： Jakob Felding ,  Hella Kohlhof ,  Manfred Groppel ,  Rolf Andreas Muhler ,  Daniel Vitt ,  Carine Chevrier ,  Mirko Zaja ,  Stefan Tasler

IPC分类号： C07D413/04 ,  C07D417/14

摘要： The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trifluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation.

公开(公告)号：US12037305B2

公开(公告)日：2024-07-16

申请号：US16981122

申请日：2019-03-15

申请人： Immunic AG

发明人： Daniel Vitt ,  Andreas Mühler ,  Manfred Gröppel ,  Hella Kohlhof

IPC分类号： C07C233/60

CPC分类号： C07C233/60 ,  C07B2200/13

摘要： Subject matter of the present invention is a white crystalline polymorph A of the Ca salt of a compound according to formula I or a solvate and/or a hydrate thereof with a molar ratio of a compound according to formula I or a solvate and/or a hydrate thereof to calcium which is 2±0.3. Subject matter of the present invention is in particular a compound according to formula I or a solvate and/or a hydrate thereof which is characterized by an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2theta at ±0.2 of the values shown below: 2 theta=5.91°, 9.64°, 16.78°, 17.81°, 19.81°, 25.41° In particular the invention refers to new polymorphs of calcium salts of the Ca salt of a compound according to formula I or a solvate and/or a hydrate thereof which inhibits dihydroorotate dehydrogenase (DHODH), a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

公开(公告)号：US20230116729A1

公开(公告)日：2023-04-13

申请号：US17992162

申请日：2022-11-22

申请人： Immunic AG

发明人： Manfred GRÖPPEL ,  Daniel Vitt ,  Hella Kohlhof ,  Andreas Mühler

IPC分类号： A61K31/196 ,  A61P19/06

摘要： The present invention refers to a 2-({3-fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and/or autoimmune diseases. The said compound of formula (I) inhibits dihydroorotate dehydrogenase (DHODH), and is known for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

公开(公告)号：US20240199535A1

公开(公告)日：2024-06-20

申请号：US18554365

申请日：2022-04-08

申请人： IMMUNIC AG

发明人： Christian GEGE ,  Hella KOHLHOF ,  Andreas MÜHLER ,  Daniel VITT

IPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

CPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

摘要： The invention relates to novel deuterated compounds of Formula (I)




and their use as medicaments.

公开(公告)号：US20240100005A1

公开(公告)日：2024-03-28

申请号：US18531121

申请日：2023-12-06

申请人： Immunic AG

发明人： Manfred GRÖPPEL ,  Daniel VITT ,  Hella KOHLHOF ,  Andreas MÜHLER

IPC分类号： A61K31/196 ,  A61P19/06

CPC分类号： A61K31/196 ,  A61P19/06

摘要： The present invention refers to a 2-({8 3-fluoro -3′-methoxy-[1,1′-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I)




and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and/or autoimmune diseases. The said compound of formula (I) inhibits dihydroorotate 10 dehydrogenase (DHODH), and is known for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

公开(公告)号：US11877995B2

公开(公告)日：2024-01-23

申请号：US17992162

申请日：2022-11-22

申请人： Immunic AG

发明人： Manfred Gröppel ,  Daniel Vitt ,  Hella Kohlhof ,  Andreas Mühler

IPC分类号： A61K31/196 ,  A61P19/06

CPC分类号： A61K31/196 ,  A61P19/06

摘要： The present invention refers to a 2-({3-fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I)




and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and/or autoimmune diseases. The said compound of formula (I) inhibits dihydroorotate dehydrogenase (DHODH), and is known for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

公开(公告)号：US20220339132A1

公开(公告)日：2022-10-27

申请号：US17855945

申请日：2022-07-01

申请人： Immunic AG

发明人： Manfred GRÖPPEL ,  Daniel VITT ,  Hella KOHLHOF ,  Andreas MÜHLER

IPC分类号： A61K31/196 ,  A61P31/14 ,  A61K9/00 ,  A61K9/20 ,  A61K31/706 ,  A61K45/06

摘要： The present invention relates to a compound according to Formula (I) or a salt, solvate and/or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.

公开(公告)号：US11376232B2

公开(公告)日：2022-07-05

申请号：US17234986

申请日：2021-04-20

申请人： Immunic AG

发明人： Manfred Gröppel ,  Daniel Vitt ,  Hella Kohlhof ,  Andreas Mühler

IPC分类号： A61K31/196 ,  A61P31/14 ,  A61K9/00 ,  A61K9/20 ,  A61K31/706 ,  A61K45/06

摘要： The present invention relates to a compound according to Formula (I) or a salt, solvate and/or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.

公开(公告)号：US20210061796A1

公开(公告)日：2021-03-04

申请号：US16644581

申请日：2018-09-06

申请人： Immunic AG

发明人： Jakob FELDING ,  Hella KOHLHOF ,  Manfred GROPPEL ,  Rolf Andreas MUHLER ,  Daniel VITT ,  Carine CHEVRIER ,  Mirko ZAJA ,  Stefan TASLER

IPC分类号： C07D413/04 ,  C07D417/14

摘要： The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trifluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation.

公开(公告)号：US20210017125A1

公开(公告)日：2021-01-21

申请号：US16981122

申请日：2019-03-15

申请人： Immunic AG

发明人： Daniel VITT ,  Andreas MÜHLER ,  Manfred GRÖPPEL ,  Hella KOHLHOF

IPC分类号： C07C233/60

摘要： Subject matter of the present invention is a white crystalline polymorph A of the Ca salt of a compound according to formula I or a solvate and/or a hydrate thereof with a molar ratio of a compound according to formula I or a solvate and/or a hydrate thereof to calcium which is 2±0.3.
Subject matter of the present invention is in particular a compound according to formula I or a solvate and/or a hydrate thereof which is characterized by an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2theta at ±0.2 of the values shown below: 2 theta=5.91°, 9.64°, 16.78°, 17.81°, 19.81°, 25.41° In particular the invention refers to new polymorphs of calcium salts of the Ca salt of a compound according to formula I or a solvate and/or a hydrate thereof which inhibits dihydroorotate dehydrogenase (DHODH), a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).